Truffle Capital — Full Portfolio
7 tracked investments · listed companies and verified rows first
Nasdaq-listed (ALT) company based in Gaithersburg, MD; Redmont portfolio company with a Hodges board seat.
Jerome Durso(Chairman of the Board, President and Chief Executive Officer)
Co-investorsBonaventure Capital
Carvolix is a French MedTech company developing AI-guided mini-robotic technologies to support interventional cardiologists in treating patients with valve dysfunction and stroke.
AI & Machine LearningBiotechHealthtechMedical DevicesRoboticsNot stated on page, EU
Philippe Pouletty(Founder of Carvolix, CEO of Truffle Capital)Sébastien Ladet(CEO of Carvolix)in
BoardMichel Therin(Chairman of the Board of Directors)
Co-investorsClaret Capital Partners
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
BiotechHealthtechMedical DevicesParis, FR
Marc de Garidel(CEO)in
Co-investorsAndera PartnersClaret Capital PartnersMedicxiSamsara BioCapitalSofinnova PartnersMorgan Stanley
Cachet provides adaptive insurance infrastructure for the platform economy, redesigning coverage as a dynamic system that moves with operators and fleets.
FintechFuture of WorkInsurTechTallinn, EE
Hedi MardisooinKalle Pallingin
Co-investorsTechstarsUNIQA Ventures GmbH
OBAT is a French SaaS for construction and building trades (BTP) professionals and artisans, offering tools for quotes, invoicing, electronic invoicing compliance, accounting export, and project/site management.
Construction TechFintechSaaS
Co-investorsIsaiISAI GestionKima VenturesEvolemHolnest
Zaion builds and orchestrates its own proprietary AI models integrated into solutions for customer service operations, automating customer interactions across voice and digital channels.
AI & Machine LearningEnterprise SoftwareSaaS
Co-investors115KBpifranceFortino Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.